Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19.

MLA

Ullah, Waqas, et al. “Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19.” Journal of Clinical Medicine Research, vol. 12, no. 7, July 2020, pp. 415–22. EBSCOhost, https://doi.org/10.14740/jocmr4227.

APA

Ullah, W., Basyal, B., Tariq, S., Almas, T., Saeed, R., Roomi, S., Haq, S., Madara, J., Boigon, M., Haas, D. C., & Fischman, D. L. (2020). Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19. Journal of Clinical Medicine Research, 12(7), 415–422. https://doi.org/10.14740/jocmr4227

Chicago

Ullah, Waqas, Bikash Basyal, Shafaq Tariq, Talal Almas, Rehan Saeed, Sohaib Roomi, Shujaul Haq, et al. 2020. “Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19.” Journal of Clinical Medicine Research 12 (7): 415–22. doi:10.14740/jocmr4227.